Merck & Co. and may own stock and/or stock options in Merck & Co. G. P. is an employee of Emory University and has a financial interest in molnupiravir. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Sean Troth,1 Joan Butterton,1 Carisa Stadlman DeAnda,1 Patricia Escobar,1 Jay Grobler,1 Daria Hazuda,1 and George Painter1,2,3,4
1Merck & Co, Kenilworth, New Jersey, USA, 2Emory Institute of Drug Development, Emory University, Atlanta, Georgia, USA, 3Drug Innovation Ventures at Emory, Atlanta, Georgia, USA, and 4Department of Pharmacology and Chemical Biology, Emory University, Atlanta, Georgia, USA

References
1. Zhou S, Hill CS, Sarkar S, et al. β-D-N 4-hydroxycytidine (NHC) inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis 2021; 224:415–9.
2. In vivo mammalian peripheral blood erythrocyte Pig-a mutation assay in rat (Charles River study no. 9800706). In: Data on file for MK-4482. Kenilworth, NJ: Merck & Co, 2021.
3. In vivo mutation assay at the cI locus in Big Blue” transgenic F344 rats (BiorReliance study no. AG23CV.171E.BTL). In: Data on file for MK-4482. Kenilworth, NJ: Merck & Co, 2021.
4. OECD. Test no. 476: in vitro mammalian peripheral blood erythrocyte Pig-a mutation assay. In: Data on file for MK-4482. Kenilworth, NJ: Merck & Co, 2021.
5. Li AP, Gupta RS, Helfich RH, Wassom JS. A review and analysis of the Chinese hamster ovary/hypoxanthine guanine phosphoribosyltransferase assay to determine the mutagenicity of chemical agents: a report of phase III of the U.S. environmental protection agency gene-tox program. Mutat Res 1998; 196:17–36.
6. Scott D, Galloway SM, Marshall RR, et al. International commission for protection against environmental mutagens and carcinogens. genotoxicity under extreme culture conditions: a report from ICPEMC task group 9. Mutat Res 1991; 257:147–205.
7. Aaron CS, Bolcsfoldi G, Glatt HR, et al. Mammalian cell gene mutation assays working group report. Mutat Res 1994; 312:235–9.

Received 7 June 2021; accepted 8 July 2021; published online July 12, 2021.
Correspondence: Sean Troth, Merck & Co, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 (sean.troth@merck.com).

The Journal of Infectious Diseases® 2021;224:1442–3 © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

LETTERS TO THE EDITOR • JID 2021;224 (15 October) • 1443

Reply to Troth et al

To the Editor—We thank Troth et al for the opportunity to extend the discussion of our data on the mutagenicity of N4-hydroxycytidine (rNHC) [1]. We view our work as providing the proof of concept showing that as a negative result (it would likely fail as a negative data using 2 in vivo model systems. Negative results must be viewed in the context of assay sensitivity. NHC mutagenesis will occur in dividing cells. Do the in vivo assays focus on dividing cells, and what is the limit of detection of new mutations when dividing cells are assessed? How do we scale these negative results to a human who may live for years? Mutagenesis is not an acute toxicity but, rather, would be revealed over a long period in cancer rates and germline mutations. Troth et al raise several questions concerning our experimental approach. First, they question our use of a 32-day drug exposure rather than a 3- to 6-hour exposure. Since rNHC has to be taken into the cell then metabolized to become a DNA precursor, a 3- to 6-hour exposure would likely result in a negative result (it would likely fail as an antiviral agent also). Short exposures are relevant to chemicals that derivatize DNA, not for metabolic precursors. Thus, it is important to think about the mechanism of mutagenesis when choosing a test for mutagenic potential, both in vitro and in vivo.

We used a short-term (5-day) cell toxicity/cytostatic assay. Troth et al suggest this should have been a 32-day assessment. While we did not do this, we also did not notice a difference in growth rate in the presence of 3 µM rNHC during the multiple rounds of cell passage.

Our results using a gene knockout model demonstrate the mutagenic potential for the host, but in our adaptation of the hypoxanthine phosphoribosyltransferase knockout model it is difficult to establish a mutation rate given that multiple rounds of cell replication and drug incorporation
occurred. Highly accurate sequencing of DNA is likely better suited to ask this question. Ultimately the rate of mutagenesis in cell culture is less relevant than the long-term consequences of exposure to a mutagen during treatment.

Troth et al pose several questions about solubility and purity. No solubility or pH issues have been noted by visual inspection, and the concentrations chosen span those obtained in the blood with anti–human immunodeficiency virus nucleoside analogs and also recently reported by Painter and colleagues studying blood levels of rNHC in people dosed with molnupiravir [2]. In addition, using these concentrations we found a dose-response pattern for incorporation of mutations in viral RNA, inconsistent with drug precipitation during culture conditions. As to purity, it would be more relevant to repeat this experiment with clinical-grade material, which we would be happy to do.

It is hard to argue that a ribonucleoside precursor to both RNA and DNA goes into one but not the other. Also, the known mutagenicity of hydroxylamine (which generates dNHC in DNA) suggests that if DNA repair could target such a small change in a base, it must do so in an incomplete way. This leads to the conclusion that treatment with molnupiravir will lead to mutations in host DNA in dividing cells. Using negative results to justify this risk as being unimportant is to create a blind spot for potential long-term harm. Until a better understanding of treatment with molnupiravir is achieved, we would argue that its use should be limited to people with co-factor risks for coronavirus disease 2019 who are likely to receive the greatest benefit while being exposed to the unknown long-term risks of exposure to this mutagen.

Notes

Financial support. This work was supported by the Antiviral Drug Discovery and Development Center (National Institutes of Health [NIH] award number U19 AI142759) and the NIH (award number R01 AI140970 to R. S.).

Potential conflicts of interest. The University of North Carolina is pursuing intellectual property protection for Primer ID and R. S. has received nominal royalties. All other authors report no potential conflicts of interest.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Shuantai Zhou,1 Collin S. Hill,1 Blaide M. D. Woodburn,2 Raymond F. Schinazi2, and Ronald Swanstrom1,4

1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, 2Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA, 3Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children’s Healthcare of Atlanta, Atlanta, Georgia, USA, and 4Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA

References

1. Zhou S, Hill CS, Sarkar S, et al. Beta-D-N 4-hydroxycytidine (NHC) inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis 2021;224:415–9.

2. Painter WP, Holman W, Bush JA, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother 2021:e02428–20.

Received 2 July 2021; editorial decision 6 July 2021; accepted 12 July 2021; published online July 13, 2021. Correspondence: Ronald Swanstrom, PhD, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Rm 22-006, Chapel Hill, NC 27599, USA (rsisunc@med.unc.edu).

The Journal of Infectious Diseases® 2021;224:1643-4

© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Potential Effect of Previous Human Coronavirus NL63 Infection on the Rate of Infection and the Clinical Course of Coronavirus Disease 2019

To the Editor—In a study of neutralizing antibodies for human coronavirus (HCoV) NL63 by Henss et al [1], the severity of coronavirus disease 2019 (COVID-19) appeared to be correlated with low HCoV-NL63 neutralizing activity, and patients with severe COVID-19 had no high-level NL63-neutralizing antibodies. However, some severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—naïve individuals analyzed in that study had high NL63-neutralizing antibodies, so the authors considered it worthwhile to explore the hypothesis that preexisting immunity to NL63 or other common cold coronaviruses might reduce the risk of severe disease.

To examine this hypothesis, we tested for the presence of HCoV-NL63 antibodies, using the human anti-HCoV-NL63 immunoglobulin G enzyme-linked immunosorbent assay kit produced by Creative Diagnostics. We tested 4 groups: individuals who were negative for SARS-CoV-2 (control group), those who tested negative even though they took care of family members with COVID-19 (high-risk contacts), patients with mild COVID-19, and patients with severe COVID-19.

In the control group (negative for SARS-CoV-2), 3 of 42 individuals tested were positive for HCoV-NL63 antibodies. This is consistent with the presumed positivity in the general population. In high-risk contacts (individuals